Autor según el artículo: Carles M; Vilaprinyo E; Cots F; Gregori A; Pla R; Román R; Sala M; Macià F; Castells X; Rue M

Departamento: Economia Medicina i Cirurgia

Autor/es de la URV: Carles Lavila, Misericòrdia / GREGORI GOMIS, ALEIX / Pla Farnòs, Roger Jesús

Palabras clave: Us Stage Screening Patterns Mortality Mammography Economic-evaluation Disease Cáncer de mama Avaluació econòmica de tecnologies sanitàries Age

Resumen: Background: Breast cancer (BC) causes more deaths than any other cancer among women in Catalonia. Early detection has contributed to the observed decline in BC mortality. However, there is debate on the optimal screening strategy. We performed an economic evaluation of 20 screening strategies taking into account the cost over time of screening and subsequent medical costs, including diagnostic confirmation, initial treatment, follow-up and advanced care.Methods: We used a probabilistic model to estimate the effect and costs over time of each scenario. The effect was measured as years of life (YL), quality-adjusted life years (QALY), and lives extended (LE). Costs of screening and treatment were obtained from the Early Detection Program and hospital databases of the IMAS-Hospital del Mar in Barcelona. The incremental cost-effectiveness ratio (ICER) was used to compare the relative costs and outcomes of different scenarios.Results: Strategies that start at ages 40 or 45 and end at 69 predominate when the effect is measured as YL or QALYs. Biennial strategies 50-69, 45-69 or annual 45-69, 40-69 and 40-74 were selected as cost-effective for both effect measures (YL or QALYs). The ICER increases considerably when moving from biennial to annual scenarios. Moving from no screening to biennial 50-69 years represented an ICER of 4,469€ per QALY.Conclusions: A reduced number of screening strategies have been selected for consideration by researchers, decision makers and policy planners. Mathematical models are useful to assess the impact and costs of BC screening in a specific geographical area. © 2011 Carles et al; licensee BioMed Central Ltd.

Áreas temáticas: Saúde coletiva Química Planejamento urbano e regional / demografia Oncology Odontología Nutrição Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar Genetics Farmacia Ensino Engenharias iii Engenharias ii Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Ciência da computação Cancer research Biotecnología Biodiversidade Administração, ciências contábeis e turismo

Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/

ISSN: 14712407

Direcció de correo del autor: rogerjesus.pla@urv.cat misericordia.carles@urv.cat

Identificador del autor: 0000-0002-3727-8933 0000-0003-3796-3014

Fecha de alta del registro: 2023-02-19

Versión del articulo depositado: info:eu-repo/semantics/publishedVersion

Enlace a la fuente original: https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-192

URL Documento de licencia: http://repositori.urv.cat/ca/proteccio-de-dades/

Referencia al articulo segun fuente origial: Bmc Cancer. 11 192-

Referencia de l'ítem segons les normes APA: Carles M; Vilaprinyo E; Cots F; Gregori A; Pla R; Román R; Sala M; Macià F; Castells X; Rue M (2011). Cost-effectiveness of early detection of breast cancer in Catalonia (Spain). Bmc Cancer, 11(), 192-. DOI: 10.1186/1471-2407-11-192

DOI del artículo: 10.1186/1471-2407-11-192

Entidad: Universitat Rovira i Virgili

Año de publicación de la revista: 2011

Tipo de publicación: Journal Publications